{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:43:25Z","timestamp":1793317405803,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.bone.2013.10.004","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T23:40:14Z","timestamp":1381448414000},"page":"11-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Bisphosphonate therapy for unresectable symptomatic benign bone tumors: A long-term prospective study of tolerance and efficacy"],"prefix":"10.1016","volume":"58","author":[{"given":"F.","family":"Cornelis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Amoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Pillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2013.10.004_bb0005","doi-asserted-by":"crossref","first-page":"225-225","DOI":"10.1056\/NEJM200107193450318","article-title":"Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis","volume":"345","author":"Arzoo","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.10.004_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00043426-200101000-00013","article-title":"Treatment of Langerhans cell histiocytosis with pamidronate","volume":"23","author":"Farran","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bone.2013.10.004_bb0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00774-008-0001-2","article-title":"Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis","volume":"27","author":"Montella","year":"2009","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.bone.2013.10.004_bb0020","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1359\/jbmr.2002.17.11.1926","article-title":"Bisphosphonate induces remission of refractory osteolysis in Langerhans cell histiocytosis","volume":"17","author":"Kamizono","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.004_bb0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2013.10.004_bb0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/sonc.2002.37420","article-title":"The antitumor potential of bisphosphonates","volume":"29","author":"Clezardin","year":"2002","journal-title":"Semin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2013.10.004_bb0035","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ctrv.2008.03.006","article-title":"Antitumor effects of bisphosphonates: promising preclinical evidence","volume":"34","author":"Guise","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bone.2013.10.004_bb0040","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.bone.2013.10.004_bb0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0305-7372(02)00095-6","article-title":"The anti-tumour activity of bisphosphonates","volume":"28","author":"Neville-Webbe","year":"2002","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bone.2013.10.004_bb0050","first-page":"231","article-title":"Bisphosphonate therapy in the management of skeletal metastases","volume":"27","author":"Grauer","year":"1998","journal-title":"Orthopade"},{"key":"10.1016\/j.bone.2013.10.004_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00223-004-0120-2","article-title":"Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone","volume":"75","author":"Cheng","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.10.004_bb0060","doi-asserted-by":"crossref","first-page":"E396","DOI":"10.1097\/BRS.0b013e31823ed70d","article-title":"Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy","volume":"37","author":"Gille","year":"2012","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.bone.2013.10.004_bb0065","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1159\/000334549","article-title":"Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor","volume":"34","author":"Chaudhary","year":"2011","journal-title":"Onkologie"},{"key":"10.1016\/j.bone.2013.10.004_bb0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bone.2007.08.038","article-title":"Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case\u2013control study","volume":"42","author":"Tse","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.004_bb0075","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s12185-011-0839-2","article-title":"Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series","volume":"93","author":"Sivendran","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bone.2013.10.004_bb0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.10.004_bb0085","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2013.10.004_bb0090","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/RCT.0b013e318227a81d","article-title":"Bone-within-bone appearance: a red flag for bisphosphonate-associated osteonecrosis of the jaw","volume":"35","author":"Fatterpekar","year":"2011","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.bone.2013.10.004_bb0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.crad.2007.04.023","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients","volume":"63","author":"Bisdas","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.bone.2013.10.004_bb0100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00256-007-0388-1","article-title":"A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid","volume":"36","author":"Quattrocchi","year":"2007","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.bone.2013.10.004_bb0105","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.joms.2007.03.030","article-title":"Adjuvant antiangiogenic therapy for giant cell tumors of the jaws","volume":"65","author":"Kaban","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.10.004_bb0110","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bone.2013.10.004_bb0115","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00586-013-2715-7","article-title":"Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts","volume":"22","author":"Lange","year":"2013","journal-title":"Eur Spine J"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213003815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213003815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T03:53:00Z","timestamp":1539316380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328213003815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":23,"alternative-id":["S8756328213003815"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2013.10.004","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonate therapy for unresectable symptomatic benign bone tumors: A long-term prospective study of tolerance and efficacy","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2013.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}